Recombinant Human ADNP protein

ADNP (Activity-Dependent Neuroprotective Protein) is a critical regulatory protein implicated in neurodevelopment, chromatin remodeling, and cognitive function. Discovered in 1999. it is highly expressed in the brain and regulated by neuronal activity. ADNP interacts with the microtubule-associated protein Tau and components of the chromatin remodeling SWI/SNF complex, playing a vital role in synaptic plasticity, autophagy, and DNA repair. Mutations in the ADNP gene cause Helsmoortel-Van der Aa syndrome, a rare neurodevelopmental disorder characterized by autism spectrum features, intellectual disability, and distinct facial traits. This link underscores ADNP’s importance in early brain development and homeostasis.

Recombinant ADNP proteins are engineered using expression systems like E. coli or mammalian cells to produce purified, functional ADNP for research and therapeutic exploration. These proteins retain key domains, including the N-terminal neuroprotective sequence and the C-terminal nuclear localization signal, enabling studies on their neuroprotective mechanisms, chromatin interactions, and disease-related mutations. Recombinant ADNP aids in elucidating molecular pathways in neurodevelopmental disorders and screening potential therapeutic compounds. Additionally, it serves as a tool for developing biologics targeting ADNP deficiency-related conditions. Current research focuses on optimizing recombinant ADNP stability, delivery methods, and preclinical validation to advance translational applications in neuroscience and precision medicine.